Blip Lozenge
Product Images NDC 82966-734

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Blip (NDC 82966-734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blip Products, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Blip-nicotine-polacrilex-lozenge-2mg-mint-carton-image.jpg (Blip Nicotine Polacrilex Lozenge 2mg Mint Carton Image)

BLIP 2 mg Nicotine Polacrilex Lozenge mini lozenge, mint flavor, stop smoking aid. The label shows a pink box containing 27 lozenges, each 2 mg. Distributed by Blip Products, Inc., New York, NY. Includes tamper-evident warnings and usage instructions. The label features a visual of the product bottle and a mint leaf graphic.*

FDA Label Image

Wallet Card Image 1 (Image 01)

An illustration titled 'WALLET CARD' featuring a prompt 'My most important reasons to quit smoking are:' followed by five blank lines for users to write down personal reasons.*

FDA Label Image

Wallet Card Image 2 (Image 02)

An informational wallet card titled 'WHERE TO CALL FOR HELP' listing three helpline phone numbers: American Lung Association, American Cancer Society, and American Heart Association, along with a prompt to contact a quitting buddy or friend who has quit.*

FDA Label Image

Smoke Free Habits Logo (Image 03)

FDA Label Image

Upc Example (Image 04)

The image shows a barcode with the text 'EXAMPLE UPC ONLY' in red centered above it. The barcode is typical for product packaging, and no other product details are visible in the image.*

FDA Label Image

Reminder Stickers (Image 05)

An illustration displaying a four-step schedule for using nicotine polacrilex lozenges, labeled STEP 1, STEP 2, STEP 3, and EX-SMOKER. Each step shows recommended frequency of lozenge use starting at week 1, week 7, and week 10, respectively, culminating in the ex-smoker stage at 12 weeks after quit date.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.